Growth Momentum Glaukos is accelerating glaucoma and corneal/retinal therapies with recent launches like iDose TR and Epioxa, reporting record first-quarter glaucoma net sales and ongoing Phase III progress, signaling expanding market adoption opportunities and potential upsell paths for ancillary ophthalmic devices and delivery systems.

New Reimbursement With CMS assigning a unique HCPCS code for Epioxa and notable CMS engagement, there is a favorable payer environment that can be leveraged to position companion products, post-market surveillance services, and reimbursement optimization offerings to ophthalmology practices and clinics.

Clinical Adoption Progress in Phase III for iLink corneal cross-linking therapy and planned U.S. approval filings indicate a growing pipeline of high-impact procedures, presenting opportunities to partner on training, adoption programs, and perioperative support tools for ophthalmic surgeons and clinics.

Strategic Partnerships Recent partnerships with nursing agencies and specialty pharmacies for Epioxa distribution point to potential collaboration opportunities in logistics, patient access programs, and bundled service offerings that can broaden reach to ophthalmology centers and managed-care networks.

Financial Scale Glaukos operates with a mid-market size profile and substantial revenue potential, suggesting a viable target for tailored technology integrations, data analytics, and service contracts that align with mid-to-large ophthalmology practices and distribution partners.